Analysts Set Personalis, Inc. (NASDAQ:PSNL) Price Target at $10.57

Shares of Personalis, Inc. (NASDAQ:PSNL) have earned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $10.5714.

Several brokerages recently weighed in on PSNL. BTIG Research raised their price target on shares of Personalis from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Lake Street Capital restated a “buy” rating and issued a $11.00 target price on shares of Personalis in a report on Wednesday, November 5th. Needham & Company LLC upped their price target on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. Finally, Morgan Stanley lifted their price objective on shares of Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st.

Insider Activity

In other Personalis news, CFO Aaron Tachibana sold 103,668 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04. Following the completion of the sale, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at approximately $1,772,857.24. This represents a 38.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Christopher M. Hall sold 29,612 shares of the stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the completion of the sale, the chief executive officer owned 148,486 shares of the company’s stock, valued at approximately $1,334,889.14. This trade represents a 16.63% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.80% of the stock is currently owned by insiders.

Institutional Trading of Personalis

A number of hedge funds have recently bought and sold shares of the business. Legal & General Group Plc bought a new position in Personalis in the 2nd quarter valued at $30,000. Ameritas Investment Partners Inc. purchased a new position in shares of Personalis in the 2nd quarter worth about $34,000. BNP Paribas Financial Markets grew its position in Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after buying an additional 5,177 shares during the period. Focus Partners Wealth purchased a new stake in Personalis during the first quarter worth about $47,000. Finally, Alpha Wealth Funds LLC bought a new stake in Personalis in the second quarter worth about $66,000. 61.91% of the stock is currently owned by institutional investors.

Personalis Trading Down 0.1%

NASDAQ PSNL opened at $7.96 on Friday. The company has a market cap of $706.85 million, a P/E ratio of -9.05 and a beta of 1.96. The company has a fifty day simple moving average of $8.86 and a 200 day simple moving average of $7.18. Personalis has a 12-month low of $2.83 and a 12-month high of $11.40.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The firm had revenue of $14.50 million for the quarter, compared to analyst estimates of $13.31 million. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. Sell-side analysts predict that Personalis will post -1.4 EPS for the current year.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.